A prospective comparative study of intravesical Bacillus Calmette-Guerin (BCG) therapy with the Tokyo or Connaught strains for non-muscle invasive bladder cancer

Trial Profile

A prospective comparative study of intravesical Bacillus Calmette-Guerin (BCG) therapy with the Tokyo or Connaught strains for non-muscle invasive bladder cancer

Suspended
Phase of Trial: Phase IV

Latest Information Update: 16 May 2016

At a glance

  • Drugs BCG (Primary) ; BCG (Primary)
  • Indications Bladder cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 07 May 2013 Results presented at the 108th Annual Meeting of the American Urological Association.
    • 19 Mar 2013 Results presented at the 28th Congress of the European Association of Urology.
    • 19 Dec 2012 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top